ChiCTR2600127148 版本V1.0 版本创建时间2026/06/25 15:08:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600127148 

最近更新日期:

Date of Last Refreshed on:

2026-06-25 15:07:46 

注册时间:

Date of Registration:

2026-06-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

带线输尿管支架的安全性研究

Public title:

Safety Study of Ureteral Stents with Strings

注册题目简写:

English Acronym:

研究课题的正式科学名称:

带线输尿管支架在输尿管镜/软镜取石术后的安全性评估:一项单中心随机对照研究

Scientific title:

Safety Evaluation of Ureteral Stents with Strings after Ureteroscopic/Flexible Ureteroscopic Lithotripsy: A Single-center Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

印英豪 

研究负责人:

印英豪 

Applicant:

Yinghao Yin 

Study leader:

Yinghao Yin 

申请注册联系人电话:

Applicant telephone:

+86 756 2528679

研究负责人电话:

Study leader's
telephone:

+86 756 252 8679

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yinyh25@mail.sysu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

yinyh25@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

珠海市香洲区梅华东路52号

研究负责人通讯地址:

珠海市香洲区梅华东路52号

Applicant address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City

Study leader's address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学附属第五医院

Applicant's institution:

The Fifth Affiliated Hospital Sun Yat sen University

研究负责人所在单位:

中山大学附属第五医院

Affiliation of the Leader:

The Fifth Affiliated Hospital Sun Yat sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

中山五院〔2025〕伦字第(K347-1)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第五医院医学伦理委员会

Name of the ethic committee:

The Fifth Affiliated Hospital Sun Yat sen University Committee on medical ethics

伦理委员会批准日期:

Date of approved by ethic committee:

2025-12-30 00:00:00

伦理委员会联系人:

傅雪婷

Contact Name of the ethic committee:

Fu XueTing

伦理委员会联系地址:

珠海市香洲区梅华东路52号

Contact Address of the ethic committee:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 756 2528895

伦理委员会联系人邮箱:

Contact email of the ethic committee:

813510375@qq.com

研究实施负责(组长)单位:

中山大学附属第五医院

Primary sponsor:

The Fifth Affiliated Hospital Sun Yat sen University

研究实施负责(组长)单位地址:

珠海市香洲区梅华东路52号

Primary sponsor's address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第五医院

具体地址:

珠海市香洲区梅华东路52号

Institution
hospital:

The Fifth Affiliated Hospital Sun Yat sen University

Address:

No. 52, Meihua East Road, Xiangzhou District, Zhuhai City

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-financed

研究疾病:

上尿路结石  

Target disease:

Upper Urinary Tract Calculi

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估带线输尿管支架在输尿管镜/软镜取石术后管理的安全性。  

Objectives of Study:

To Evaluate the Safety of Ureteral Stents with Strings in Postoperative Management of Ureteroscopic/Flexible Ureteroscopic Lithotripsy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.自愿签署知情同意书的患者;
2.年龄18岁以上且具备完全民事行为能力的患者;
3.经中国泌尿外科和男科疾病诊断治疗指南,规范诊断为上尿路结石(包括输尿管结石和(或)肾结石);并拟行输尿管镜碎石取石或输尿管软镜碎石取石术的患者;

Inclusion criteria

1.Patients who have voluntarily signed the informed consent form.
2.Patients aged over 18 years old with full capacity for civil conduct.
3.Patients who have been standardly diagnosed with upper urinary tract calculi (including ureteral calculi and/or renal calculi) in accordance with the Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases in China, and are scheduled to undergo ureteroscopic lithotripsy or flexible ureteroscopic lithotripsy.

排除标准:

1.尿路感染未得到控制的患者,符合以下标准: 1.伴有尿路症状的患者:清洁中段尿培养:菌落计数≥10? CFU/mL(单一致病菌);或清洁中段尿离心沉渣:白细胞酯酶(+)或尿白细胞计数≥10个/ HPF(高倍视野),且尿培养菌落计数≥103 CFU/mL(单一致病菌); 2.无尿路症状的患者:连续 2 次清洁中段尿培养,均为同一单一致病菌,且菌落计数≥10? CFU/mL;
2.对输尿管镜/软镜手术有绝对禁忌症的患者;
3.患者无法理解或配合试验的开展;
4.需要做经皮肾镜手术患者;
5.术后需要长期留置输尿管支架超过4周+2天的患者;
6.研究者认为可能存在增加受试者危险性或干扰临床试验的任何情况;

Exclusion criteria:

1. Patients with uncontrolled urinary tract infections (UTIs) who meet the following criteria: (1) Patients with urinary tract symptoms: Clean-catch midstream urine culture: colony count >= 10^5 CFU/mL (single pathogenic bacterium); OR centrifuged sediment of clean-catch midstream urine: leukocyte esterase (+) or urine leukocyte count >= 10 cells/HPF (high-power field), plus urine culture colony count >= 10^3 CFU/mL (single pathogenic bacterium). (2) Patients without urinary tract symptoms: Two consecutive clean-catch midstream urine cultures showing the same single pathogenic bacterium, with colony count >= 10^5 CFU/mL in both tests. 2. Patients with absolute contraindications to ureteroscopic/flexible ureteroscopic surgery. 3. Patients who are unable to understand or cooperate with the conduct of the trial. 4. Patients requiring percutaneous nephrolithotomy (PCNL). 5. Patients who need long-term indwelling ureteral stents for more than 4 weeks and 2 days after surgery. 6. Patients with any other conditions that the investigators believe may increase risks to the participants or interfere with the clinical trial.

研究实施时间:

Study execute time:

From 2026-01-15 00:00:00 To 2027-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-25 00:00:00 To 2026-10-31 00:00:00

干预措施:

Interventions:

组别:

研究组(2周)

样本量:

64

Group:

Research group (2 weeks)

Sample size:

干预措施:

术后留置带线输尿管支架,术后2周拔除

干预措施代码:

Intervention:

A string-attached ureteral stent was indwelled postoperatively and removed two weeks after surgery.

Intervention code:

组别:

对照组(4周)

样本量:

64

Group:

control group(4 weeks)

Sample size:

干预措施:

术后留置普通输尿管支架,术后4周经膀胱镜拔除

干预措施代码:

Intervention:

A conventional ureteral stent is indwelled postoperatively and removed via cystoscopy four weeks after surgery.

Intervention code:

组别:

对照组(2周)

样本量:

64

Group:

control group(2 weeks)

Sample size:

干预措施:

术后留置普通输尿管支架,术后2周经膀胱镜拔除

干预措施代码:

Intervention:

A conventional ureteral stent is indwelled postoperatively and removed via cystoscopy two weeks after surgery.

Intervention code:

组别:

研究组(4周)

样本量:

64

Group:

Research group (4 weeks)

Sample size:

干预措施:

术后留置带线输尿管支架,术后4周拔除

干预措施代码:

Intervention:

A string-attached ureteral stent was indwelled postoperatively and removed four weeks after surgery.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第五医院 

单位级别:

三级甲等 

Institution
hospital:

The Fifth Affiliated Hospital Sun Yat sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血常规(白细胞计数等)

指标类型:

次要指标

Outcome:

complete blood count(white blood cell count etc.)

Type:

Secondary indicator

测量时间点:

筛选期,术后1日、2周或1日、4周

测量方法:

送检血液样本至检验科进行血常规检测

Measure time point of outcome:

Screening period,after surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

Submit the blood specimen to the clinical laboratory for complete blood count (CBC).

指标中文名:

术后尿路感染发生率

指标类型:

主要指标

Outcome:

Postoperative urinary tract infection rate

Type:

Primary indicator

测量时间点:

筛选期,术后1日、2周,或1日、4周

测量方法:

送检尿液至检验科进行尿培养检查

Measure time point of outcome:

Screening period,after surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

Submit the urine specimen to the clinical laboratory for urine culture

指标中文名:

输尿管支架症状 (USSQ)

指标类型:

次要指标

Outcome:

Ureteral stent symptom

Type:

Secondary indicator

测量时间点:

术后1日、2周或1日、4周

测量方法:

患者填写问卷

Measure time point of outcome:

After surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

participants fill out the questionnaire

指标中文名:

不良事件发生率

指标类型:

次要指标

Outcome:

Adverse event rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膀胱过度活动症状评分

指标类型:

次要指标

Outcome:

Overactive Bladder Symptom Score (OABSS)

Type:

Secondary indicator

测量时间点:

筛选期,术后1日、2周或1日、4周

测量方法:

患者填写膀胱过度活动症状量表

Measure time point of outcome:

Screening period,after surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

participants complete Overactive Bladder Symptom Score (OABSS) Questionnaire

指标中文名:

LUTS症状

指标类型:

次要指标

Outcome:

Lower urinary tract symptoms

Type:

Secondary indicator

测量时间点:

筛选期,术后1日、2周或1日、4周

测量方法:

患者填写问卷

Measure time point of outcome:

Screening period,after surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

participants fill out the questionnaire

指标中文名:

视觉模拟量表(VAS)

指标类型:

次要指标

Outcome:

visual analogue scale

Type:

Secondary indicator

测量时间点:

术后1日、2周或1日、4周

测量方法:

患者填写问卷

Measure time point of outcome:

After surgery at 1 day,2 weeks or at 1 day ,4weeks.

Measure method:

participants fill out the questionnaire

指标中文名:

降钙素原

指标类型:

次要指标

Outcome:

Procalcitonin

Type:

Secondary indicator

测量时间点:

筛选器,术后1日

测量方法:

送血液样本至检验科检测

Measure time point of outcome:

Screening period,after surgery at 1 day

Measure method:

Send blood samples to the clinical laboratory for testing.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究负责入组的研究者通过随机数生成器,随机生成1,2两个数字,1进入研究组使用带线输尿管支架,2则进入对照组使用普通输尿管支架。

Randomization Procedure (please state who generates the random number sequence and by what method):

The investigators responsible for patient enrollment in this study generated two random numbers (1 and 2) using a random number generator. Patients assigned the number 1 were allocated to the study group and received string-attached ureteral stents, while those assigned the number 2 were allocated to the control group and received conventional ureteral stents.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open-label study

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后半年内,国家人口健康科学数据中心,https://www.ncmi.cn/index.html

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the paper is published,National Population Health Science Data Center, https://www.ncmi.cn/index.html

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病历记录表(CRF)和问卷收集进行数据采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management were conducted via case report forms (CRFs) and questionnaire surveys.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-25 15:07:46